Contents
Vol 3, Issue 85
Contents
Perspective
- Rituximab’s New Therapeutic Target: The Podocyte Actin Cytoskeleton
A well-characterized monoclonal antibody drug imparts therapeutic benefit in kidney disease through an off-target–mediated mechanism.
Research Articles
- Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis
Rituximab treatment in high-risk patients with focal segmental glomerulosclerosis directly affects podocyte function and is linked to reduced incidence of recurrent proteinuria after kidney transplantation.
- A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma
Signaling through the VHL-PTP1B-Src pathway in renal cell carcinomas may determine sensitivity to Src inhibitors and provide a basis for treatment planning.
- MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines
Adjuvant use improves the quality and quantity of the immune response to pandemic influenza vaccines.
Editors' Choice
- DPP4 Joins Weight Watchers
In patients with metabolic syndrome, human visceral fat secretes an adipokine DPP4 that impairs insulin signaling in muscle, potentially contributing to insulin resistance.
- Old Dogs and New Tricks
A combination of standard cytotoxic chemotherapies used for other cancers extends overall survival for pancreatic cancer patients.
- Molecular Sleuthing: Linking Leprosy and Armadillos
Investigators use molecular epidemiology to link leprosy with armadillo exposure, suggesting a new zoonotic mode of transmission.
- The Changing Brain
Spinal cord injury can potentially lead to adaptive changes in the sensory and motor cortical areas of the brain.